Scientists have found that people with lung cancer have high levels of a protein in their blood,paving way for development of a simple blood test to diagnose the disease.
Researchers found that a protein called isocitrate dehydrogenase (IDH1) is present at high levels in lung cancers and can be a diagnostic marker for the disease.
“This study is the first to report identification of IDH1 as a novel biomarker for the diagnosis of non-small cell lung cancers (NSCLC) using a large number of clinical samples,” said Jie He,director of the Laboratory of Thoracic Surgery at the Peking Union Medical College and Chinese Academy of Medical Sciences in Beijing.
“Lung cancer has a high mortality rate,mostly because of late diagnosis. With an increase in ageing population,we are likely to see an increase in lung cancer incidence and a need for better biomarkers for early diagnosis.
“We have identified IDH1 as an effective plasma biomarker with high sensitivity and specificity in the diagnosis of NSCLC,especially lung adenocarcinoma,” He said.
He and colleagues found that IDH1 could be detected in the blood of lung cancer patients with 76 per cent sensitivity and 77 per cent specificity.
When they used a mathematical model to combine the detection of IDH1 with the detection of existing markers,the sensitivity increased to 86 per cent.
“Based on the present data,IDH1 can be used to detect stage 1 lung cancer; however,it is also possible that IDH1 could be used to detect precancer but further studies are required to address that possibility,” said He.
He and colleagues used blood samples collected from 943 patients with NSCLC and 479 healthy controls,enrolled between 2007 and 2011 in the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences.
None of the study participants had a cancer diagnosis,nor were they treated for cancer in the three years prior to the study.
Researchers measured the levels of IDH1 and other existing markers in the participants’ blood.
The researchers then divided the samples into a training set and a test set to validate the detection efficiency of IDH1.
They found the data obtained from the test set were as good as those from the training set,demonstrating the robustness of IDH1 as a biomarker for lung cancer diagnosis.
“Our research also suggests IDH1 may be involved in the development of lung cancer,and it may be a good target for the treatment of NSCLC,” said He.
The study was published in Clinical Cancer Research,a journal of the American Association for Cancer Research.